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DObjective: Patients with hypertrophic obstructive cardiomyopathy due to diffuse hypertrophy extending to or
below the papillary muscles are poor candidates for alcohol septal ablation and suboptimal candidates for
transaortic septal myectomy. In addition, the outflow obstruction is often aggravated by an abnormal mitral valve
and subvalvular apparatus.
Methods: We performed transatrial myectomy in 12 patients with diffuse hypertrophy, who were highly
symptomatic despite maximal medical therapy. All had at least moderate mitral regurgitation and systolic
anterior motion. The anterior mitral leaflet (AML) was detached from commissure to commissure, allowing
an easy myectomy through this AML toward the base of the anterior papillary muscle, with mobility fully
restored. The abnormal chordae from the septum to the anterior papillary muscle and AML were divided.
The continuity of this AML was restored with augmentation using an autologous pericardial patch. The height
of the posterior mitral leaflet was reduced and the repair completed using an oversized annuloplasty ring.
Results: The peak intraventricular gradients decreased spectacularly from 98.8  6.29 to 19.2  13.4 mm Hg
(P< .001), and the systolic anterior motion and mitral regurgitation disappeared. One patient died of left
ventricular diastolic dysfunction. All other patients left the hospital in New York Heart Association class I or II.
Conclusions: We believe that this technique is preferable for patients with hypertrophic obstructive
cardiomyopathy and diffuse hypertrophy extending to the midportion of the left ventricle or beyond. It results in
disappearance of outflow tract gradients and allows correction of themitral valve abnormality. (JThoracCardiovasc
Surg 2014;147:1833-6)Transaortic extended surgical septal myectomy (SSM) has
generally been accepted as the preferred treatment of
hypertrophic obstructive cardiomyopathy (HOCM) in
patients with severe drug-refractory symptoms. This
technique has been associated with very low mortality,
consistent alleviation of outflow gradients and related
symptoms, and excellent long-term survival.1
However, in recent years, the primary treatment strategy
for typical asymmetric septal hypertrophy has, particularly
in Europe, shifted toward percutaneous alcohol septal
ablation (ASA), despite the suboptimal results in terms of
complications, persistent symptoms, and the need for
pacemaker implantation.2 Thus, most contemporary surgi-
cal candidates will present with diffuse hypertrophyhe Department of Cardiac Surgerya and Department of Anesthesia and
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The Journal of Thoracic and Carextending to or below the papillary muscles (PMs), with
midcavity muscular obstruction. These patients are poor
candidates for ASA but are also suboptimal candidates for
the Morrow procedure.
In addition, the outflow obstruction in these patients will
often be aggravated by an abnormal mitral valve and
subvalvular apparatus. The PMs can be displaced anteroapi-
cally or can be attached, or even embedded, in the septal
muscular hypertrophy. The posterior mitral leaflet (PML)
is often longer with a diminished coaptation–septal dis-
tance. This results, together with a narrowed aortic–mitral
angle, in systolic anterior motion (SAM) of the mitral
valve.3,4 Although the SAM causes mitral regurgitation
(MR), great interindividual difference can occur for
comparable degrees of SAM, depending on the geometry
of the mitral valve and subvalvular apparatus. The
incidence of some degree of MR in patients with HOCM
has been reported to be up to 95%,1 necessitating mitral
valve repair in 20% of cases.4 Centers with a large experi-
ence have repeatedly shown a decrease in both SAM and
MR with an adequately performed extended SSM.1,5
However, the persistence of SAM or MR after SSM can
be difficult to predict, and treatment remains
controversial, because mitral valve repair in the setting of
HOCM can be challenging.diovascular Surgery c Volume 147, Number 6 1833
Abbreviations and Acronyms
AML ¼ anterior mitral valve leaflet
ASA ¼ alcohol septal ablation
HOCM ¼ hypertrophic obstructive cardiomyopathy
LVOT ¼ left ventricular outflow tract
MR ¼ mitral regurgitation
PML ¼ posterior mitral leaflet
PM(s) ¼ papillary muscle(s)
SAM ¼ systolic anterior motion
SSM ¼ surgical septal myectomy
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DMETHODS
Patient Selection
From January 2010 to March 2013, we operated on 12 patients with
diffuse obstructive hypertrophy. The indications for SSM included drug-
refractory class III or IV symptoms (n ¼ 11), an episode of heart failure
(n ¼ 1), and a blood pressure decrease of more than 10 mm Hg at peak
exercise (n ¼ 3). One patient had undergone previous ASA.
Patient Characteristics
The mean patient age was 53.0  10.5 years (range, 34-61), and 83%
were men. All 12 patients had diffuse hypertrophy extending below the
level of the PMs, with an average peak left ventricular outflow tract
(LVOT) gradient of 98.8  6.29 mm Hg and a mean septal thickness
of 25  6 mm. Most patients (92%) had moderate to severe MR
(mean 2.6 0.8) and SAM. The color flow jet of the MRwas either central
or posteriorly directed, suggesting the SAM was responsible for the MR.Surgical Data
All patients underwent surgery under normothermia, with a mean
cardiopulmonary bypass time of 243  88 minutes. Intermittent antegrade
warm blood cardioplegia was administered every 15 minutes for 3 or more
minutes. The mean aortic crossclamping time was 148  30 minutes.
The mitral valve was exposed through a transatrial septal approach.
The anterior mitral valve leaflet (AML) was detached from the annulus
from commissure to commissure, providing excellent exposure of the
septum to the apex of the heart. SSM was then performed, starting 5
mm under the aortic annulus just in the middle of the insertion of the
AML. It was prolonged horizontally to the left to the limit of the outflow
tract, with a depth of at least 1.5 cm less than the preoperatively measured
depth. The myectomy was taken downward to the base of the anterior
PMs over the same thickness, preferably in 1 block, using the combina-
tion of a no. 11 bladed knife and a stitch cutter, which allowed for
easy appreciation of the resection depth. The mean depth of this muscle
resection was 11.7  2.89 mm. Starting the resection at the midpoint of
the AML insertion prevents injury to the bundle of His, which is situated
in the vicinity of the mitral posteromedial commissure. The anterior PM
embedded in the hypertrophy was carefully mobilized, and abnormal
chordae from the septum toward the anterior PM and AML were divided
(Figure 1). The AML was reconstructed with an autologous untreated
pericardial patch, generously sized in breadth and height to account for
the stitching space, using a running locked 5-0 polypropylene suture
(Pronova, Johnson & Johnson, New Brunswick, NJ). If the height of
the PML was more than 2 cm (92% of cases), the PML was incised 5
mm from, and parallel to, the posterior annulus and resutured, reducing
the height to approximately 1 cm. The height of the ‘‘new’’ AML was
measured, and a corresponding complete and semirigid ring (Physio II,
Edwards LifeSciences, Irvine, Calif) was implanted, carefully avoiding
undersizing (mean size, 34.0  1.6).1834 The Journal of Thoracic and Cardiovascular SurStatistical Analysis
Statistical analyses were performed using Statistica statistical software
(StatSoft, Tulsa, Okla). The results for the continuous data are reported as
the mean standard deviation or median and range, as appropriate. Paired
t tests were used to compare continuous parameters, and discontinuous
data were compared using the Fisher exact test. P<.05 was considered
statistically significant.RESULTS
Intraoperative transesophageal echocardiography
showed a reduction in the interventricular thickness from
25 6 mm to 15 3 mm (P<.001). There was no or trivial
MR (grade, 0.71  0.49), with a mean coaptation length of
9.2  0.7 mm and a posterior shift of the coaptation site,
resulting in the complete disappearance of the SAM in all
patients. Transthoracic echocardiography at discharge
showed a spectacular alleviation of the peak intraventricular
gradients (98.8  6.29 vs 19.2  13.4 mm Hg, P<.001).
Patch augmentation of theAML is time-consuming; how-
ever, the longer aortic crossclamping time (mean, 148 30
minutes) did not result in greater postoperative troponin T
levels, despite the hypertrophy. In addition, the long aortic
crossclamping time did not correspond to the ischemic
time in our practice, because we have chosen to optimize
the myocardial protection in these hypertrophic hearts by
delivering warm blood cardioplegia for 3 to 4 minutes every
15 minutes. However, after unclamping the aorta, the sub-
optimal diastolic function required a precise optimization
of the preload and, therefore, a longer reperfusion time.
In 1 patient, severe pulmonary hypertension persisted
(preoperative systolic pulmonary artery pressure, 80 mm
Hg), with subsequent pulmonary edema immediately
after weaning from cardiopulmonary bypass, necessitating
the use of extracorporeal membrane oxygenation. He
eventually died of left ventricular diastolic dysfunction
and subsequent right ventricular failure. The other 11
patients were discharged after a median hospital stay of
15 days, and after 4 weeks, all were in New York Heart
Association class I or II. One patient required a pacemaker
for complete atrioventricular block (right bundle branch
block was present after previous ASA).DISCUSSION
The technique of leaflet extension (through the aortic
valve) and transmitral myectomy have been previously
described6-8; however, we have used a combination of
transmitral myectomy with the classic Carpentier
techniques of mitral valve repair.Diffuse Hypertrophy With Embedded Papillary
Muscles
Despite the excellent long-term results and low
complication rate of SSM, the use of ASA has continued to
increase, especially in Europe. Therefore, contemporarygery c June 2014
FIGURE 1. Intraoperative view. Arrow 1 indicates detached anterior
mitral leaflet; arrow 2, septum resection started at the 12-o’clock position
and extending toward the aortic valve; and arrow 3, the fully liberated
anterior papillary muscle.
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Dsurgical candidates no longer present with the typical asym-
metric hypertrophy, but with a diffuse form, extending to or
below the PMs. Although some high-volume centers have re-
ported transaortic extendedmyectomy down to the level of the
PMs, going beyond and freeing them from the hypertrophic
muscle remains very challenging through the aortic valve.1,5
In the case of apical or midventricular hypertrophy, some
investigators have therefore promoted a transapical approach.9
With the transmitral approach, the myectomy can be
easily extended to the apex, and the papillary muscles can
be safely liberated from the ventricular wall under direct
vision, restoring full mobility of the subvalvular apparatus.
A transseptal approach ensures an optimal exposure of the
mitral valve in such cases.
Mitral Valve and Subvalvular Abnormalities
In addition to septal hypertrophy, other contributors to
dynamic LVOT obstruction have been described, in parti-
cular, mitral leaflet and subvalvular pathologic features.4,10FIGURE 2. Transesophageal echocardiographic images before and after surger
(between arrows).
The Journal of Thoracic and CarAbnormal papillary muscle morphology, including
anteroapical displacement and bifid papillary muscles,
has been associated with dynamic LVOT obstruction, inde-
pendent of the basal septal thickness.4 Some investigators
have promoted PM reorientation, fixing them to the
posterior left ventricle to displace the leaflet coaptation
posteriorly.4 A similar result, however, can be obtained by
the combination of augmenting the AML and freeing the
anterior PM.
The mitral leaflet length of the AML and/or PML will be
abnormal on magnetic resonance imaging in 30% of
patients with HOCM,3 making them extremely vulnerable
for residual SAM, and the incidence of SAM after extended
SMM can be up to 52%.1 An elongated PML is not
infrequent and might be an acquired phenomenon, resulting
from the Venturi suction of the mitral coaptation in the
outflow tract.
Several techniques have been proposed to treat the aber-
rant mitral valve, such as retentionplasty, AML plication,
the Alfieri stitch, and AML extension.6,10 The extension
technique showed good results, with no SAM and a
residual MI grade greater than I in 3% of patients.6 The
investigators hypothesized that this was because the patch
stiffened the AML, making it less likely to buckle in the
presence of Venturi and flow drag forces. In our technique,
we have used a large untreated autologous pericardial patch,
which is even weaker than the native leaflet. Therefore, in
systole, the patch enlarges the outflow tract, eliminating
the Venturi and drag forces, on the condition that complete
deployment of this enlarged AML is possible (Figure 2) by
freeing the anterior PM and reducing the PML height.
We have observed such a nice enlargement of the outflow
tract that we have tended to become less aggressive with the
myectomy. We also believe that valve replacement, even in
the difficult setting of HOCM, can nearly always be
avoided.
We had 1 perioperative death, for a mortality rate of 8%
in this small study sample. However, these 12 patients didy. Note the bulging of the patch away from the left ventricular outflow tract
diovascular Surgery c Volume 147, Number 6 1835
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Dnot have classic HOCM with basal septal hypertrophy, for
which we know that myectomy can be performed with
almost no mortality.1 The patients in the present study all
had diffuse hypertrophy of the left ventricle and therefore
were prone to left ventricular diastolic dysfunction after
myectomy.
Study Limitations
The present study lacked long-term follow-up data.
However, the echocardiographic measurements showed a
complete alleviation of the LVOT gradient, with a wide
open outflow tract. The mitral repair used classic Carpentier
techniques with their proven durability.
CONCLUSIONS
LVOTobstruction is multifactorial, and we do not believe
that 1 technique is appropriate for all patients. We believe
this technique is the treatment of choice for contemporary
surgical candidates with diffuse hypertrophy extending to
or below the level of the PMs.
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